Moderna (MRNA) closed at $41.95 in the latest trading session, marking a +2.29% move from the prior day. The stock's change was more than the S&P 500's daily gain of 0.47%. Meanwhile, the Dow ...

Once one of the biggest winners of the pandemic era, Moderna (MRNA) saw explosive growth as demand for its COVID-19 vaccine ...

As single-stock leveraged ETFs continue to proliferate, Defiance ETFs last week added a 2X Moderna Inc MRNA-linked fund, the Defiance Daily Target 2X Long MRNA ETF MRNX, targeting traders looking for ...

Moderna (MRNA) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Cramer called the week an extraordinary one, as he pointed out that the Dow Jones Industrial Average crossed 50,000. He recalled that the Dow was around 1,000 when he first walked down the same street ...

Moderna (MRNA) is back in focus after pairing a new rare disease collaboration on mRNA-3927 with Recordati with a leadership ...

S&P 500, Dow Jones Industrial Average, US Small Cap 2000, Cisco Systems Inc. Read 's Market Analysis on Investing.com ...

You can’t blame this one on the stork. After a brief baby bump early in the COVID-19 pandemic, birth rates in the US and ...

Arbutus Biotech (ABUS) heads to a key March Moderna LNP patent trial as imdusiran HBV milestones drive value—get the latest ...

Wall Street expects a year-over-year decline in earnings on lower revenues when Moderna (MRNA) reports results for the ...

We recently published an article titled 11 High Growth Micro-cap Stocks to Buy. On January 6, Citi lowered its price target ...

Eli Lilly to buy Orna Therapeutics, which focuses on ‘in vivo’ CAR-T for autoimmune diseases, for $2.4 billion ...